Vulnerability and Exploitation in Clinical Trials Conducted in Low-Income Settings

Abstract

Clinical trials conducted in low-income countries raise a persistent worry that sponsors are drawn there by lower costs and thinner oversight, and that consent from populations dependent on the trial for care cannot bear the ethical weight placed on it.
This review traces that worry from the 1990s standard-of-care debate over placebo-controlled perinatal HIV-transmission trials through the fair-benefits and responsiveness frameworks it produced, distinguishing vulnerability, a diminished capacity to protect one's own interests, from exploitation, taking disproportionate  advantage of that diminished capacity. It then examines how dependency on a trial for basic healthcare strains standard consent doctrine, how undue inducement can render modest incentives effectively irresistible, and how uneven regulatory oversight and unenforced post-trial access commitments leave gaps that procedural safeguards alone do not close. We argue that vulnerability and exploitation are frequently conflated, and that a population can be vulnerable without being exploited when investigators calibrate design, consent, and benefit-sharing to that vulnerability
rather than taking advantage of it. We conclude that defensible research in low-income settings requires standard-of-care justification,
negotiated benefit-sharing, consent suited to conditions of dependency, and credible local oversight operating together, not as substitutes for one another.